Tissue IGF-I Measured by Microdialysis Reflects Body Glucose Utilization After rhIGF-I Injection in Type 1 Diabetes

The Journal of Clinical Endocrinology and Metabolism
Klas EkströmPeter Bang

Abstract

Type 1 diabetes is associated with portal insulin deficiency and disturbances in the GH-IGF axis including low circulating IGF-I and GH hypersecretion. Whether peripheral hyperinsulinemia and GH hypersecretion, which are relevant to the development of vascular complications, result in elevated tissue IGF-I remains unknown. The purpose of this study was to determine the relationship between whole-body glucose uptake and tissue IGF-I measured by microdialysis. This was a single-blind placebo-controlled crossover study. The setting was a tertiary pediatric endocrine referral center. The participants were seven young male adults with type 1 diabetes. After an overnight fast, a 6-h lasting euglycemic clamp was performed (constant insulin infusion at 0.5 mU/kg × minute and variable glucose infusion rate [GIR]) and a subcutaneous injection of recombinant human (rh) IGF-I (120 μg/kg) or saline was given after 2 hours. In parallel, tissue IGF-I levels were determined by microdialysis (md-IGF-I). md-IGF-I levels in muscle and subcutaneous fat, and GIR were determined. md-IGF-I levels were detectable but unchanged after saline. After rhIGF-I, muscle and subcutaneous fat md-IGF-I increased during the second and third hour and then reached ...Continue Reading

Citations

Mar 16, 2019·Frontiers in Endocrinology·Juan Ignacio BertucciSuraj Unniappan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.